• Drugs Made in America Acquisition Corp. held an extraordinary general meeting on April 27, 2026.
• Shareholders adopted a charter amendment to allow up to 12 one-month extensions of business-combination deadline from April 29, 2026 to April 29, 2027.
• Extension remains conditional on sponsor deposits of lesser of $300,000 or $0.04 per non-redeemed public share for each one-month extension period into trust account.
• Adjournment resolution was not presented, since sufficient votes were available to pass extension amendment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051018), on May 01, 2026, and is solely responsible for the information contained therein.